Mirum Pharmaceuticals, Inc. (MIRM)
Mirum Pharmaceuticals, Inc. (MIRM)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -790,155 | -5,730 | 2,905 | -20,538 |
| Stock-based compensation | 36,202 | 19,026 | 18,127 | 34,271 |
| Depreciation and amortization | 6,874 | 6,074 | 6,062 | 12,108 |
| Inventory reserves and firm commitment losses | 0 | 0 | -540 | -2,349 |
| Amortization of debt discount and offering costs | 454 | 436 | 443 | 860 |
| Loss from termination of revenue interest purchase agreement | NaN | 0 | NaN | NaN |
| Non-cash interest expense related to the revenue interest liability | NaN | 0 | NaN | NaN |
| Unrealized foreign exchange loss (gain) | -1,098 | -193 | 643 | 1,270 |
| Non-cash lease expense | 550 | 457 | 447 | 826 |
| Fair value of common stock issued in connection with asset acquisition | 415,271 | NaN | NaN | NaN |
| Change in fair value of holdback liabilities | 998 | NaN | NaN | NaN |
| Other | 278 | 382 | 345 | 674 |
| Accounts receivable | 12,886 | 19,008 | 3,146 | 25,901 |
| Prepaid and other current assets | 6,630 | -5,990 | 4,632 | 7,114 |
| Inventory | 1,920 | 2,282 | 1,159 | 5,007 |
| Other assets | 4,796 | 1,637 | 2,684 | 1,342 |
| Accounts payable, accrued expenses and other liabilities | 57,244 | 3,443 | 24,346 | 22,314 |
| Holdback liabilities | 71,790 | NaN | NaN | NaN |
| Operating lease liabilities | -583 | -513 | -580 | -803 |
| Net cash used in operating activities | -228,763 | 6,067 | 39,681 | 10,079 |
| Purchase of investments | 34,797 | 11,502 | 20,860 | 65,063 |
| Proceeds from maturities of investments | 33,892 | 13,108 | 18,820 | 42,497 |
| Purchase of property and equipment | 664 | 600 | 187 | 167 |
| Cash paid for acquisition | NaN | 0 | NaN | NaN |
| Payments made for additions to intangible assets | 10,000 | 0 | 0 | 0 |
| Net cash used in investing activities | -11,569 | 1,006 | -2,227 | -22,733 |
| Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs | 259,948 | 0 | NaN | NaN |
| Proceeds from issuance of common stock in at-the-market offerings, net of issuance costs | NaN | 0 | NaN | NaN |
| Proceeds from issuance of convertible notes, net | NaN | 0 | NaN | NaN |
| Proceeds from issuance of common stock pursuant to equity plans | 10,131 | 8,999 | 16,096 | 15,047 |
| Payments of deferred offering costs | NaN | 0 | NaN | NaN |
| Payments on revenue interest liability | NaN | 0 | NaN | NaN |
| Net cash provided by financing activities | 270,079 | 8,999 | 16,096 | 15,047 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | -1,272 | -408 | 349 | 3,281 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 28,475 | 15,664 | 53,899 | 5,674 |
| Cash, cash equivalents and restricted cash at beginning of period | 298,165 | 282,501 | 222,928 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 326,640 | 298,165 | 282,501 | NaN |